Biotech Daily Special Report November 21, 2006
November 21st 2006 06:33
Psiron Applies
For Phase I
‘Late Stage’ Cancer Trial
For Phase I
‘Late Stage’ Cancer Trial
Psiron has requested ethics approval for a phase I dose escalation trial of intravenous Cavatak for late stage breast, prostate and melanoma cancer patients.
Psiron has recruited clinical investigators for the trial to assess safety, with secondary objectives being signs of efficacy.
The company said Cavatak demonstrated “significant efficacy when administered intravenously” in animal models growing human, breast, prostate and melanoma tumors.
Psiron said that while early stage melanoma, breast and prostate cancers could be successfully treated by various modalities, few effective treatments exist for cancers which have progressed to stage IV. No current therapies are curative. There is currently an unmet need for an effective treatment for stage IV patients with these types of solid tumors.
In the US prostate cancer is the most frequent cancer type diagnosed in males, with 200,000 new patients a year, while breast cancer is the most frequent cancer diagnosed in females with more than 200,000 patients a year.
Melanoma is one of the fastest growing cancers based on frequency, with more than 50,000 new patients each year in the US.
Yesterday Psiron announced verbal approval for a phase I intra-tumor stage IV melanoma trial.
Psiron fell half a cent or 3.45 percent to 14 cents.
Other stories in today’s Biotech Daily
available by daily email subscription
click here
* ASX UP BIOTECHS DOWN: USCOM UP 14%, CYGENICS DOWN 10%
* PRANA RAISES $7.8m FOR ‘IMMEDIATE’ ALZHEIMER’S TRIAL
* MESOBLAST FILES IND FOR US SPINAL FUSION TRIAL
* PORTLAND IN $6m ‘DEMAND EXCEEDS SUPPLY’ PLACEMENT
* ROCKEBY INVESTS IN PEOPLE’S DISTRIBUTOR
* PEPTECH TO LIST ON LONDON’S AIM
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 29 |
| Vote |
Add To: 
subscribe to this blog